Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659599 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL20281001 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL3276506 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL16431695 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL17866955 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL9985445 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL3281934 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL2338047 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL448041 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL7153437 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| CN-117843739-A | Campylobacter jejuni surface trisaccharide conjugate and preparation method and application thereof | 江苏食品药品职业技术学院 | 2024-04-09 | — | — | CN | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| US-10765627-B2 | Immunogenic composition against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190336440-A1 | Immunogenic Composition Against Campylobacter Jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2019-11-07 | — | — | US | disclosed |
| US-9308246-B2 | Capsule composition for use as immunogen against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2016022412-A1 | IMMUNOGENIC COMPOSITION AGAINST CAMPYLOBACTER JEJUNI | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20150273037-A1 | Immunogenic composition against Campylobacter jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2015-10-01 | — | — | US | disclosed |
| US-20150031863-A1 | CONJUGATING AMINES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2013009826-A9 | CONJUGATING AMINES | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013009826-A1 | CONJUGATING AMINES | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2012166587-A1 | CAPSULE COMPOSITION FOR USE AS IMMUNOGEN AGAINST CAMPYLOBACTER JEJUNI | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20110300173-A1 | Capsule composition for use as immunogen against Campylobacter jejuni | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2011-12-08 | — | — | US | disclosed |
| WO-2005017129-A1 | PHOSPHORAMIDE AND USES THEREOF | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2005-02-24 | — | — | WO | disclosed |
| US-5157116-A | Antidiabetic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300173-A1 | Capsule composition for use as immunogen against Campylobacter jejuni | CAPG, ST3GAL3, ICOS | AKR1B1 4337/4885MPI 630/4885LMNA 4219/4885 |
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885LMNA 1219/4885 |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885LMNA 1219/4885 |
| US-10765627-B2 | Immunogenic composition against Campylobacter jejuni | TLR6, TLR2, SIGLEC9 | AKR1B1 3981/4885MPI 208/4885LMNA 3469/4885 |
| US-20190336440-A1 | Immunogenic Composition Against Campylobacter Jejuni | TLR6, TLR2, SIGLEC9 | AKR1B1 3981/4885MPI 208/4885LMNA 3469/4885 |
| US-20150031863-A1 | CONJUGATING AMINES | CD47, CD58, CD44 | AKR1B1 3571/4885MPI 2736/4885LMNA 2936/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885LMNA 1219/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885LMNA 1219/4885 |
| US-20150273037-A1 | Immunogenic composition against Campylobacter jejuni | TLR6, TLR2, TLR9 | AKR1B1 3982/4885MPI 221/4885LMNA 3446/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885LMNA 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.